Page 38 - Read Online

Page 14 of 14 Lozano-Rosas et al. Hepatoma Res 2018;4:19 I http://dx.doi.org/10.20517/2394-5079.2018.48

81. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122--a key factor and therapeutic target in liver disease. J Hepatol 2015;62:448-57.
82. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS,
Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122:2884-97.
83. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, Khatsenko OG,
Kaimal V, Lees CJ, Fernandez-Hernando C, Fisher EA, Temel RE, Moore KJ. Inhibition of miR-33a/b in non-human primates raises
plasma HDL and lowers VLDL triglycerides. Nature 2011;478:404-7.
84. Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC,
Esplugues E, Fisher EA, Penalva LO, Moore KJ, Suarez Y, Lai EC, Fernandez-Hernando C. miR-33a/b contribute to the regulation of
fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011;108:9232-7.
85. Qiao L, Ru G, Mao Z, Wang C, Nie Z, Li Q, Huang-Yang Y, Zhu L, Liang X, Yu J, Jiang P. Mitochondrial DNA depletion,
mitochondrial mutations and high TFAM expression in hepatocellular carcinoma. Oncotarget 2017;8:84373-83.
86. Machida K. Existence of cancer stem cells in hepatocellular carcinoma: myth or reality? Hepatol Int 2017;11:143-7.
87. Chen CL, Uthaya Kumar DB, Punj V, Xu J, Sher L, Tahara SM, Hess S, Machida K. NANOG metabolically reprograms tumor-initiating
stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metab 2016;23:206-19.
88. Machida K. Pluripotency transcription factors and metabolic reprogramming of mitochondria in tumor-initiating stem-like cells.
Antioxid Redox Signal 2017; doi: 10.1089/ars.2017.7241.
89. Lee WT, St John J. The control of mitochondrial DNA replication during development and tumorigenesis. Ann N Y Acad Sci
2015;1350:95-106.
90. Yamada S, Nomoto S, Fujii T, Kaneko T, Takeda S, Inoue S, Kanazumi N, Nakao A. Correlation between copy number of mitochondrial
DNA and clinico-pathologic parameters of hepatocellular carcinoma. Eur J Surg Oncol 2006;32:303-7.
91. Shen F, Huang W, Qi JH, Yuan BF, Huang JT, Zhou X, Feng YQ, Liu YJ, Liu SM. Association of 5-methylcytosine and
5-hydroxymethylcytosine with mitochondrial DNA content and clinical and biochemical parameters in hepatocellular carcinoma. PLoS
One 2013;8:e76967.
92. Xie CH, Naito A, Mizumachi T, Evans TT, Douglas MG, Cooney CA, Fan CY, Higuchi M. Mitochondrial regulation of cancer
associated nuclear DNA methylation. Biochem Biophys Res Commun 2007;364:656-61.
93. Boix L, Lopez-Oliva JM, Rhodes AC, Bruix J. Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy
through Smad-independent TGF-beta pathway. Oncotarget 2016;7:71309-29.
94. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S,
Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific
Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
95. Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for hepatocellular carcinoma. Biomark Cancer 2017;9:1-9.
96. Berridge MV, Dong L, Neuzil J. Mitochondrial DNA in tumor initiation, progression, and metastasis: role of horizontal mtDNA transfer.
Cancer Res 2015;75:3203-8.
97. Pasquier J, Guerrouahen BS, Al Thawadi H, Ghiabi P, Maleki M, Abu-Kaoud N, Jacob A, Mirshahi M, Galas L, Rafii S, Le Foll F, Rafii A.
Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. J Transl
Med 2013;11:94.
98. Chatterjee A, Dasgupta S, Sidransky D. Mitochondrial subversion in cancer. Cancer Prev Res (Phila) 2011;4:638-54.
99. Chu MP, Kriangkum J, Venner CP, Sandhu I, Hewitt J, Belch AR, Pilarski LM. Addressing heterogeneity of individual blood cancers:
the need for single cell analysis. Cell Biol Toxicol 2017;33:83-97.
100. Wang W, Gao D, Wang X. Can single-cell RNA sequencing crack the mystery of cells? Cell Biol Toxicol 2018;34:1-6.
101. Wang W, Wang X. Single-cell CRISPR screening in drug resistance. Cell Biol Toxicol 2017;33:207-10.
102. Qian M, Spada C, Wang X. Approach, application, and bioethics of mtDNA sequencing in cancer. Adv Exp Med Biol 2017;1038:23-38.
103. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K. Downregulation of miR-122 in the rodent and human
hepatocellular carcinomas. J Cell Biochem 2006;99:671-8.
104. Thakral S, Ghoshal K. miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as
miRNA mimic and antimir. Curr Gene Ther 2015;15:142-50.